Olanzapine

BreastfeedingGeriatricPediatric
  • TRADE NAMES: Symbyax (Lilly); Zyprexa (Lilly); Zyprexa Relprevv (Lilly)
  • INDICATIONS: Schizophrenia, bipolar I disorder
  • CLASS: Antipsychotic, Muscarinic antagonist
  • HALF-LIFE: 21–54 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alcohol, Antihypertensive agents, Carbamazepine, Ciprofloxacin, CNS acting drugs, Diazepam, Dopamine agonists, Eszopiclone, Fluoxetine, Fluvoxamine, Insulin Degludec, Insulin Detemir, Insulin Glargine, Levodopa, Lithium, Metoclopramide, Tetrabenazine, Valproic Acid

PREGNANCY CATEGORY: C

Can cause DRESS and other serious skin reactions.

Symbyax is olanzapine and fluoxetine; Zypraxa Relprevv is olanzapine pamoate.

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Zyprexa Relprevv: POST-INJECTION DELIRIUM/SEDATION SYNDROME


See full prescribing information for complete boxed warning.

Our database has 202 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of olanzapine in the Taylor & Francis journal Expert Opinion on Drug Safety. See also a separate review of olanzapine in combination with fluoxetine in the drug profile for fluoxetine. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top